Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $5.62B
• Dividend Yield: N/A
• Average Volume (3M): 3.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.16
• Revenue Growth: -86.13%
• EPS Growth: -67.29%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -1.58
• Shares Outstanding: 86,363,686
• 10 Day Avg. Volume: 4,006,039
• 30 Day Avg. Volume: 3,671,557
• PEG Ratio: 3.58
• Price to Book (P/B): 2.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.45
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 9.96
• Enterprise Value/Gross Profit: -53.49
• Enterprise Value/Ebitda: -3.06
• 1Y Price Target: $69.38
• Price Target Upside: 6.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 21

• Rating: 64 Neutral
• Price Target: $70.00 ▲(7.15%Upside)

CRISPR Therapeutics AG's overall stock score is driven by positive technical momentum and strategic corporate developments, offset by financial challenges and valuation concerns. The company's strong technical indicators suggest bullish market sentiment, while its ongoing strategic partnerships and advancements in therapy development offer long-term growth potential. However, the financial performance highlights significant risks, particularly in revenue generation and profitability, which weigh down the overall score.

Positive Factors

Collaborations and acquisitions

The recently reported acquisition of Verve by Lilly offers validation to Crispr's approach in genetic editing.

Financial performance

Crispr is uniquely positioned to achieve its goals due to its lead industry position and robust balance sheet.

Technological advancements

CRISPR Therapeutics' diverse and robust pipeline, with key technologies passing through several derisking hoops, positions it well in the gene editing landscape.

Negative Factors

Data release delays

Delaying CTX320 Lp(a) data - a catalyst to diversify the story beyond Casgevy commercial launch - is a disappointment.

Strategic considerations

Strategic rationale for delaying CTX320 data is to better contextualize the results with the upcoming Novartis and Ionis Phase 3 HORIZON readout for pelacarsen.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics AG generates revenue primarily through collaborations and strategic partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales resulting from successful commercialization of jointly developed therapies. Additionally, Crispr Therapeutics may receive research grants and government funding to support its development of gene-editing therapies. The company also aims to commercialize its own drug candidates, which, upon regulatory approval, would provide another revenue stream in the form of product sales.

Crispr Therapeutics AG Financial Statement Overview

Summary

Crispr Therapeutics AG faces significant financial challenges, particularly in revenue generation and profitability. Despite a strong balance sheet with substantial equity and cash reserves, the company struggles with negative income and cash flow metrics. These issues highlight the need for improved operational efficiency and revenue growth strategies to ensure financial sustainability.

Income Statement

Crispr Therapeutics AG has shown significant volatility in revenue and profit margins. The most recent annual report indicates a drastic revenue decline compared to previous years, with a sharp drop from 2021 to 2024. Gross and net profit margins have turned negative, highlighting operational challenges and high expenses relative to revenue. The TTM data shows a negative EBIT and EBITDA margin, indicating operational inefficiencies and ongoing financial struggles.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting stability in its capital structure. While the debt-to-equity ratio is relatively low, indicating manageable leverage, the stockholders' equity has slightly declined over the years. The balance sheet reflects a solid cash position, which is crucial for a biotech firm investing in R&D, despite the negative net income.

Cash Flow

Crispr Therapeutics AG exhibits a negative free cash flow trend, with operating cash flows consistently negative over recent years. This indicates potential liquidity challenges. The free cash flow to net income ratio is also negative, underscoring ongoing cash management issues. The cash flow from financing has been positive, which may provide temporary relief but signifies reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.00M	371.21M	436.00K	913.08M	543.00K
Gross Profit	-75.25M	240.96M	-109.81M	895.13M	-268.86M
EBITDA	-447.31M	-202.70M	-648.99M	391.48M	-345.25M
Net Income	-366.25M	-153.61M	-650.17M	377.66M	-348.87M
Balance Sheet
Total Assets	2.24B	2.23B	2.24B	2.75B	1.83B
Cash, Cash Equivalents and Short-Term Investments	1.90B	1.69B	1.82B	2.38B	1.69B
Total Debt	223.69M	238.63M	244.02M	225.03M	61.43M
Total Liabilities	309.95M	346.77M	367.58M	352.42M	163.73M
Stockholders Equity	1.93B	1.88B	1.88B	2.40B	1.66B
Cash Flow
Free Cash Flow	-144.68M	-272.35M	-532.93M	457.27M	-256.72M
Operating Cash Flow	-142.77M	-260.38M	-495.74M	538.97M	-238.37M
Investing Cash Flow	-280.48M	374.65M	-258.65M	-1.04B	-541.17M
Financing Cash Flow	331.98M	62.66M	38.59M	250.94M	1.02B

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 65.33 is above the 20-day moving average (MA) of 53.34, above the 50-day MA of 44.75, and above the 200-day MA of 43.74, indicating a bullish trend. The MACD of 4.81 indicates Negative momentum. The RSI at 75.73 is Negative, neither overbought nor oversold. The STOCH value of 67.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	80 Outperform	$2.02B	13.44	24.71%	―	20.62%	14.08%
CRSP	64 Neutral	$5.62B	―	-19.71%	―	-86.13%	-67.29%
NTLA	60 Neutral	$1.25B	―	-57.92%	―	-13.37%	2.57%
BEAM	56 Neutral	$2.09B	―	-38.04%	―	-82.38%	-164.76%
ARQT	54 Neutral	$1.75B	―	-70.58%	―	100.03%	64.22%
VERV	52 Neutral	$972.55M	―	-34.26%	―	271.44%	26.65%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%

Crispr Therapeutics AG Corporate Events

CRISPR Therapeutics Updates on Cardiovascular Programs

On June 26, 2025, CRISPR Therapeutics AG announced updates on its in vivo cardiovascular disease programs, including new data for CTX310™, CTX320™, and CTX340™. CTX310™, targeting ANGPTL3, continues to show promising results in reducing triglycerides and low-density lipoprotein in its Phase 1 trial, with peak reductions of up to 82% and 86% respectively, without significant liver enzyme changes. CTX320™, targeting the LPA gene, is in an ongoing Phase 1 trial, with an update expected in the first half of 2026. Meanwhile, CTX340™, targeting angiotensinogen for refractory hypertension, is progressing through preclinical studies. These developments highlight CRISPR Therapeutics AG’s strategic advancements in addressing cardiovascular diseases, potentially impacting its market position and offering new treatment avenues for patients.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

CRISPR Therapeutics AG Shareholders Approve Key Proposals

On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Crispr Therapeutics AG Partners with Sirius on siRNA Tech

On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.